Menu

Notable Science Quotes

Eugene Garfield, the cancer moonshot, employee genetic testing, and more

Apr 1, 2017
The Scientist Staff

Eugene Garfield: 1925–2017ILLUSTRATION BY ERICA P. JOHNSON

Everything he did, he was ahead of everybody in so many ways. He was a genius of a very special type. Not only because he had this incredible imagination and brain, but he had incredible tenacity and courage.

—Vitek Tracz, publisher of Faculty of 1000 and former co-owner of The Scientist, on the passing of Eugene Garfield, the scientometrics pioneer who launched The Scientist in 1986 (February 27)

 

I think that measuring with precision human activity on the climate is something very challenging to do, and there’s tremendous disagreement about the degree of impact, so no, I would not agree that it’s a primary contributor to the global warming that we see.

Newly confirmed US Environmental Protection Agency Administrator Scott Pruitt, on the CNBC program Squawk Box (March 9)

 

It is my hope that this new administration, once it gets organized—and I’m not being facetious—can be as committed and enthusiastic as we were. The only bipartisan thing left in America is the fight against cancer.

Former Vice President Joe Biden, in a speech delivered at this year’s South by Southwest festival in Austin, Texas, about the federal government’s role in cancer research (March 12)

 

To succeed, the Trump administration needs to assume the leadership Biden was given previously as vice president to foster cooperation and collaboration among the various federal agencies and institutions with relevant resources, and to guide [the] moonshot in a direction that maximizes its value to public health.

—Nancy Brinker, founder of the Susan G. Komen breast cancer charity, and journalist Eric Rosenthal, writing in The Hill about how Donald Trump should pursue Barack Obama’s cancer “moonshot” (February 15)

 

His treatment was much easier than what some people have to endure, but I’ve found that physicians who have a cancer experience understand the human side of things and how treatment impacts individuals and families.

—Shelley Fuld Nasso, CEO of the National Coalition for Cancer Survivorship, talking about Donald Trump’s appointment of  Scott Gottlieb— a physician, drug industry financier, and cancer survivor—to lead the US Food and Drug Administration (March 10)

 

It would allow employers to ask employees invasive questions about . . . genetic tests they and their families have undergone . . . [and] to impose stiff financial penalties on employees who choose to keep such information private, thus empowering employers to coerce their employees.

—Nancy Cox, president of the American Society of Human Genetics, in a letter delivered to the House Committee on Education and the Workforce a day before it approved HR 1313, a bill that would allow companies to require their workers to undergo genetic testing or pay fines (March 10)

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!